Literature DB >> 26725094

Clinicopathologic features of small cell glioblastomas.

Hiroaki Takeuchi1, Ryuhei Kitai2, Tetsuya Hosoda2, Shinsuke Yamada2, Norichika Hashimoto2, Ken-ichiro Kikuta2, Yukio Shimizu3, Hirohiko Kimura3,4.   

Abstract

Small cell glioblastoma (SCGBM) is a variant of glioblastomas characterized by a predominant population of small and monomorphic glial cells. The aim of the present study was to investigate clinical, neuroimaging, pathologic, and genetic features of SCGBM. The clinicopathologic and genetic features were evaluated in 14 patients with SCGBM. All cases were divided into multifocal and solitary type by MRI, and extent of microvascular proliferation, intratumoral necrosis, and perivascular lymphocytic accumulation were investigated. IDH1 mutations by immunohistochemistry (IDH1 R132H) and 1p 19q codeletion by fluorescence in situ hybridization were detected. Patients ranged from 23 to 92 years of age (median: 71 years), with three females and eleven males. The overall survival time of the patients ranged from 7 to 23 months (mean: 11 months). Nine patients (64%) were the multifocal type. Pathologic study revealed that the microvascular proliferation, necrosis, and lymphocytic infiltration were limited in SCGBM. Immunohistochemically, tumor cells were negative for IDH1 R132H in all patients. FISH analysis demonstrated that no SCGBM had 1p/19q codeletion in informative patients. Our investigation suggested that an elderly onset and multifocal lesions were characteristics of SCGBM associated with degradation of the immune response, infiltrative feature of tumor cells, and an unfavorable prognosis.

Entities:  

Keywords:  Immune response; MRI; Multifocal; Small cell glioblastoma

Mesh:

Substances:

Year:  2016        PMID: 26725094     DOI: 10.1007/s11060-015-2038-0

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  19 in total

1.  Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas.

Authors:  G S Bauman; Y Ino; K Ueki; M C Zlatescu; B J Fisher; D R Macdonald; L Stitt; D N Louis; J G Cairncross
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-10-01       Impact factor: 7.038

2.  Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas.

Authors:  J S Smith; A Perry; T J Borell; H K Lee; J O'Fallon; S M Hosek; D Kimmel; A Yates; P C Burger; B W Scheithauer; R B Jenkins
Journal:  J Clin Oncol       Date:  2000-02       Impact factor: 44.544

3.  Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis.

Authors:  Y Ino; R A Betensky; M C Zlatescu; H Sasaki; D R Macdonald; A O Stemmer-Rachamimov; D A Ramsay; J G Cairncross; D N Louis
Journal:  Clin Cancer Res       Date:  2001-04       Impact factor: 12.531

4.  Malignant monstrocellular brain tumours. A study of 42 surgically treated cases.

Authors:  L Palma; P Celli; A Maleci; N Di Lorenzo; G Cantore
Journal:  Acta Neurochir (Wien)       Date:  1989       Impact factor: 2.216

5.  Temozolomide chemotherapy in recurrent oligodendroglioma.

Authors:  M J van den Bent; F Keime-Guibert; A A Brandes; M J Taphoorn; J M Kros; F A Eskens; A F Carpentier
Journal:  Neurology       Date:  2001-07-24       Impact factor: 9.910

6.  The incidence of multifocal cerebral gliomas. A histologic study of large hemisphere sections.

Authors:  R O Barnard; J F Geddes
Journal:  Cancer       Date:  1987-10-01       Impact factor: 6.860

7.  Small cell architecture--a histological equivalent of EGFR amplification in glioblastoma multiforme?

Authors:  P C Burger; D K Pearl; K Aldape; A J Yates; B W Scheithauer; S M Passe; R B Jenkins; C D James
Journal:  J Neuropathol Exp Neurol       Date:  2001-11       Impact factor: 3.685

8.  Proliferation of vascular smooth muscle cells in glioblastoma multiforme.

Authors:  Hiroaki Takeuchi; Norichika Hashimoto; Ryuhei Kitai; Toshihiko Kubota; Ken-ichiro Kikuta
Journal:  J Neurosurg       Date:  2010-08       Impact factor: 5.115

9.  Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.

Authors:  J G Cairncross; K Ueki; M C Zlatescu; D K Lisle; D M Finkelstein; R R Hammond; J S Silver; P C Stark; D R Macdonald; Y Ino; D A Ramsay; D N Louis
Journal:  J Natl Cancer Inst       Date:  1998-10-07       Impact factor: 13.506

10.  Giant cell glioblastoma: a glioblastoma subtype with distinct epidemiology and superior prognosis.

Authors:  Kevin R Kozak; John S Moody
Journal:  Neuro Oncol       Date:  2009-12       Impact factor: 12.300

View more
  1 in total

1.  Dramatic clinical response in the treatment of small cell glioblastoma multiforme.

Authors:  Farzana Yasmin Zaman; Catriona McLean; Malaka Ameratunga
Journal:  J Clin Pharm Ther       Date:  2022-01-11       Impact factor: 2.145

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.